AUR-106 / Dr. Reddy’s, Aurigene - LARVOL DELTA

JIVAN: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (clinicaltrials.gov) - P1 | N=21 | Terminated | Sponsor: Aurigene Discovery Technologies Limited | N=30 ➔ 21 | Trial completion date: Jun 2025 ➔ Feb 2026 | Recruiting ➔ Terminated | Trial primary completion date: May 2025 ➔ Feb 2026; Patient recruitment problems

Enrollment change • First-in-human • Trial completion date • Trial primary completion date • Trial termination • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer

JIVAN: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Aurigene Discovery Technologies Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • CD4 • CD8 • IFNG • IL2 • IL6 • NCAM1

JIVAN: A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Aurigene Discovery Technologies Limited

Metastases • New P1 trial • Colon Cancer • Colorectal Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Kidney Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer